389 related articles for article (PubMed ID: 19923864)
21. Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Sibaud V; Delord JP; Chevreau C
Target Oncol; 2009 Dec; 4(4):307-10. PubMed ID: 19894099
[TBL] [Abstract][Full Text] [Related]
22. [6-mercaptopurine-related hand-foot syndrome in a four-year-old child].
Giacchero D; Monpoux F; Chiavérini C; Lacour JP
Ann Dermatol Venereol; 2008; 135(8-9):580-3. PubMed ID: 18789293
[TBL] [Abstract][Full Text] [Related]
23. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse.
Manchen E; Robert C; Porta C
J Support Oncol; 2011; 9(1):13-23. PubMed ID: 21465734
[TBL] [Abstract][Full Text] [Related]
24. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Porta C; Paglino C; Imarisio I; Bonomi L
Clin Exp Med; 2007 Dec; 7(4):127-34. PubMed ID: 18188524
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib-associated hand-foot syndrome in Japanese patients.
Iijima M; Fukino K; Adachi M; Tsukamoto T; Murai M; Naito S; Minami H; Furuse J; Akaza H
J Dermatol; 2011 Mar; 38(3):261-6. PubMed ID: 21342228
[TBL] [Abstract][Full Text] [Related]
26. Erythema multiforme-like drug reaction to sorafenib.
Lewin J; Farley-Loftus R; Pomeranz MK
J Drugs Dermatol; 2011 Dec; 10(12):1462-3. PubMed ID: 22134572
[TBL] [Abstract][Full Text] [Related]
27. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
28. Penile involvement with hand-foot syndrome.
Sorscher SM
Am J Clin Dermatol; 2004; 5(3):209-10. PubMed ID: 15186201
[TBL] [Abstract][Full Text] [Related]
29. Successful topical treatment of sorafenib-induced hand-foot skin reaction in a child with hepatocellular carcinoma.
Hütten M; Lassay L; Sachs B; Deutz P; Mertens R; Baron JM; Merk HF; Ott H
Pediatr Dermatol; 2009; 26(3):349-50. PubMed ID: 19706105
[TBL] [Abstract][Full Text] [Related]
30. The hand-foot syndrome--a frequent secondary manifestation in antineoplastic chemotherapy.
Janusch M; Fischer M; Marsch WCh; Holzhausen HJ; Kegel T; Helmbold P
Eur J Dermatol; 2006; 16(5):494-9. PubMed ID: 17101468
[TBL] [Abstract][Full Text] [Related]
31. [Dermatologic toxicity to sorafenib].
Velázquez D; de la Cueva P; Zamberk P; Lázaro P
Actas Dermosifiliogr; 2009; 100(6):518-20. PubMed ID: 19709563
[No Abstract] [Full Text] [Related]
32. Reader seeks clarification on hand-foot skin reaction.
Clark M
Clin J Oncol Nurs; 2008 Jun; 12(3):395; author reply 395. PubMed ID: 18564457
[No Abstract] [Full Text] [Related]
33. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Wollenberg A; Staehler M; Eames T
Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
[TBL] [Abstract][Full Text] [Related]
34. Risk of bleeding not increased by sorafenib or sunitinib.
Minor DR
Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763
[No Abstract] [Full Text] [Related]
35. Chemotherapy-induced palmer planter erythrodysesthesia.
Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
[TBL] [Abstract][Full Text] [Related]
36. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
37. Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Beldner M; Jacobson M; Burges GE; Dewaay D; Maize JC; Chaudhary UB
Oncologist; 2007 Oct; 12(10):1178-82. PubMed ID: 17962611
[TBL] [Abstract][Full Text] [Related]
38. Palmar-plantar erythrodysesthesia secondary to sunitinib treatment resulting in necrotic foot syndrome aggravated by background diabetic vascular disease.
Guenova E; Weber HO; Voykov B; Metzler G; Mitev V; Berneburg M; Hoetzenecker W; Röcken M
Arch Dermatol; 2008 Aug; 144(8):1081-2. PubMed ID: 18711102
[No Abstract] [Full Text] [Related]
39. [Palmoplantar erythrodysesthesia after intravenous therapy with docetaxel].
Meller S; Reifenberger J; Stege H; Ruzicka T; Homey B
Hautarzt; 2005 Oct; 56(10):965-6. PubMed ID: 16142497
[No Abstract] [Full Text] [Related]
40. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]